Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 937-237-2 | CAS number: 1370006-50-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Remarks:
- Type of genotoxicity: gene mutation
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2002-08-30 to 2003-01-30
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Read-across from a guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 003
- Report date:
- 2003
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- July 21, 1997
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.17 (Mutagenicity - In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- June 08, 2000
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian cell gene mutation assay
Test material
- Reference substance name:
- oleic-acid based IQAC, DMS quaternised
- IUPAC Name:
- oleic-acid based IQAC, DMS quaternised
- Reference substance name:
- Imidazolium compounds, 2-C17-unsatd.-alkyl-1-(2-C18-unsatd. amidoethyl)-4,5-dihydro-N-methyl, Me sulfates
- IUPAC Name:
- Imidazolium compounds, 2-C17-unsatd.-alkyl-1-(2-C18-unsatd. amidoethyl)-4,5-dihydro-N-methyl, Me sulfates
Constituent 1
Constituent 2
Method
- Target gene:
- This in vitro experiment assesses the potential of the test item to induce gene mutations by means of a Thymidine Kinase assay using the mouse lymphoma cell line L5178Y. The Thymidine Kinase (TK) system detects base pair mutations, frameshift mutations, small deletions as well as large, non lethal deletions and rearrangements of the relevant chromosomes.
Cells deficient in the heterozygous TK-Iocus due to the forward mutation TK+/- to TK-/- are resistant to the cytotoxic effects of pyrimidine analogues such as trifluorothymidine (TFT).
Species / strain
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- - Type and identity of media: RPMI 1640 medium
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes
- Periodically checked for karyotype stability: yes
- Periodically "cleansed" against high spontaneous background: yes
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 fractions obtained from livers of male Wistar rats which were induced with Phenobarbital (80 mg/kg b.w.) and ß-Naphthoflavone (100 mg/kg b.w.). Final protein concentration of 0.75 mg/mI in the cultures.
- Test concentrations with justification for top dose:
- The selection of the concentrations was based on data from a pre-experiment.
Experiment I
- with metabolic activation: 2.50, 5.00, 7.50, 10.0, 12.5, 15.0, 20.0, 40.0 and 60.0 µg/ml
- without metabolic activation: 1.00, 3.00, 5.00, 10.0, 12.0, 16.0, 18.0, 20.0, 25.0 and 30.0 µg/ml
Experiment II
- with metabolic activation: 10.0, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0 and 55.0 µg/ml
- without metabolic activation: 0.50, 1.00, 2.00, 4.00, 6.00, 8.00, 10.0, 12.0 and 16.0 µg/ml - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: The solvent was compatible with the survival of the cells and the S9 activity.
Controlsopen allclose all
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- ethylmethanesulphonate
- Remarks:
- Migrated to IUCLID6: 80 and 400 µg/ml without metabolic activation
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- Remarks:
- Migrated to IUCLID6: 1.50 µg/ml with metabolic activation
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: experiment I short time incubation 4 hours and experiment II long-term incubation 24 hours
- Expression time (cells in growth medium): 72 hours in experiment I and 48 h in experiment II
- Selection time (if incubation with a selection agent): 11 to 14 days
- Fixation time (start of exposure up to fixation or harvest of cells): 14 to 17 days
SELECTION AGENT (mutation assays): trifluorothymidine (TFT)
NUMBER OF REPLICATIONS: two
NUMBER OF CELLS EVALUATED: 300000/plate seeded
DETERMINATION OF CYTOTOXICITY
- Method: relative total growth, cloning efficiency - Evaluation criteria:
- There are several criteria for determining a positive result:
- clear and dose-related increase in the mutant frequency,
- biologically relevant response (at least 2-fold increase of mutant frequencies related to the comparable negative control values and higher than the historical range of negative controls) for at least one of the dose groups.
- combined with a positive effect in the mutant frequency, an increased occurrence of small colonies (slow growth colonies) indicated by a low large/small colonies ratio (< 4), is an indication for potential clastogenic effects and/or chromosomal aberrations.
According to the OECD guidelines, the biological relevance of the results is the criterion for the interpretation of results, a statistical evaluation of the results is not regarded as necessary.
A test item is considered to be negative if there is no biologically relevant increase in the induction of mutant cells above concurrent control levels, at
any dose level.
Results and discussion
Test results
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- at concentrations >/= 16 µg/plate
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- The selection of the concentrations was based on data from the pre-experiment. Precipitation of the test item in cell culture medium was observed at concentrations of 50.0 µg/ml and higher. The pH-value detected at a test item concentration of 200 µg/ml was 7.2.
TOXICITY:
Growth inhibition was observed in experiment I and II with and without metabolic activation.
In experiment I with metabolic activation the relative total growth (RTG) was 6.85 % for the highest concentration (60.0 µg/ml) evaluated. The highest biologically relevant dose group evaluated with metabolic activation was 40.0 µg/ml with a RTG of 16.19 %. The highest concentration investigated without metabolic activation was 30.0 µg/ml with a RTG of 7.62 %. The highest biologically relevant concentration evaluated without metabolic activation was 20.0 µg/ml with a RTG of 10.19 %.
In experiment II with metabolic activation the relative total growth (RTG) was 13.04 % for the highest concentration (55.0 µg/ml) evaluated. The highest biologically relevant concentration evaluated without metabolic activation was 16.0 g/ml with a RTG of 17.14 %.
MUTAGENICITY:
In experiment I with metabolic activation all mutant values found were within the historical control data of the test facility BSL BIOSERVICE (about 20-150 mutants per 10exp6 cells). No dose effect relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the controls.
Mutation frequencies with the negative controls were 66.39 - 100.61 mutants/10exp6 cells. The values of the solvent controls were found to be 64.18 - 90.07 mutants/10exp6 cells and 46.56 - 133.57 mutants/10exp6 cells with the test item, respectively. The highest mutation factor (compared to the solvent control values) of 1.73 was found at a concentration of 60.0 µg/ml with a RTG of 6.85 %. The mutation factor found at this dose group was considered as not biologically relevant due to the high toxicity found. The highest biologically relevant concentration evaluated was 40.0 µg/ml and showed a mutation factor of 1.07.
In experiment I without metabolic activation all mutant values found were within the historical control data of the test facility BSL BIOSERVICE (about 20-150 mutants per 10exp6 cells) except the value (172.70 mutants/10exp6 cells) found at a dose of 25.0 µg/ml. No dose dependency could be observed. Due to the high cytotoxicity of 8.93 % RTG at 25.0 µg/ml the increased mutation factor (above the historical control data) was considered as not biologically relevant. Moreover, if the spontaneous mutant frequency (negative control) is > 100 mutants/10exp6 cell, a doubling of the spontaneous frequency should be required for a definitive positive response. The mutation factor found at a dose of 25.0 µg/ml was 1.45, thus below the threshold value of 2.
Mutation frequencies with the negative controls were 100.99 - 136.72 mutants/10exp6 cells. The values of the solvent controls were found to be 102.49 - 135.07 mutant/10exp6 cells and 65.22 - 172.70 mutants/10exp 6 cells with the test item, respectively. The highest mutation factor (compared to the solvent control values) of 1.45 was found at a concentration of 25.0 µg/ml with a RTG of 8.93 %. The highest biologically relevant dose group
evaluated (20.0 µg/ml) showed a mutation factor of 1.02.
In experiment II with metabolic activation all mutant values found were within the historical control data of the test facility BSL BIOSERVICE (about 20-150 mutants per 10exp6 cells). No dose effect relationship could be observed. The mutation frequencies found in the groups treated with the test item did not show a biologically relevant increase as compared to the controls.
Mutation frequencies with the negative controls were 64.80 - 68.94 mutants/10exp6 cells. The values of the solvent controls were found to be 62.71 - 103.15 mutants/10exp6 cells and 40.30 - 88.61 mutants/10exp6 cells with the test item, respectively. The highest mutation factor (compared to the solvent control values) of 1.07 was found at a concentration of 15.0 µg/ml with a RTG of 91.69 %.
In experiment II without metabolic activation all mutant values found were within the historical control data of the test facility BSL BIOSERVICE (about 20-150 mutants per 10exp6 cells). No dose effect relationship could be observed. The mutation factor of 2, which was found at a dose of 0.50 µg/ml, was considered as not relevant due to the mutant frequency of 136.84 mutants/10exp6 cells, which was within the historical control data.
Mutation frequencies with the negative controls were 76.86 - 111.59 mutants/10exp6 cells. The values of the solvent controls were found to be 64.67 - 72.05 mutants/l0exp6 cells and 49.86 - 136.84 mutants/l0exp6 cells with the test item, respectively. The highest mutation factor (compared to the solvent control values) of 2.00 was found at a concentration of 0.50 µg/ml with a RTG of 83.16 %.
EMS (80 µg/ml and 400 µg/ml) and B[a]P (1.50 µg/ml) were used as positive controls and showed distinct and biologically relevant effects in mutation frequency.
RELATIONSHIP TO LARGE AND SMALL COLONIES:
Colony sizing was performed for the highest concentrations of the test item and for the negative and positive controls. A mutation frequency above 2 in combination with an increased occurrence of small colonies (defined by slow growth and/or morphological alteration of the cell clone), indicated by a low large/small colonies ratio (< 4), is an indication for potential clastogenic effects and/or chromosomal aberrations.
In experiment I, with metabolic activation the quotients of large/small colonies of the negative controls were found to be 14.00 and 73.00. For the
solvent controls the quotients noticed were 7.43 and 10.33. The quotient of the highest dose groups were found to be 17.00 (15.0 µg/ml), 14.50
(20.0 µg/ml), 15.00 (40.0 µg/ml) and 10.38 (60.0 µg/ml). No indication of potential clastogenic effects and/or chromosomal aberrations was found in all dose groups evaluated.
In experiment I without metabolic activation the quotients of large/small colonies of the negative controls were found to be 12.60 and 26.00. For the
solvent controls the quotients noticed were 5.91 and 10.43. The quotients of the highest dose groups were found to be 14.50 (18.0 µg/ml), 7.89
(20.0 µg/ml), 4.89 (25.0 µg/mI) and 7.45 (30.0 µg/ml). No indication of potential clastogenic effects and/or chromosomal aberrations was found in
all dose groups evaluated.
In experiment II with metabolic activation the quotients of large/small colonies of the negative controls were found to be 7.38 and 11.60. For the
solvent controls the quotients noticed were 7.67 and 9.40. The quotients of the highest dose groups were found to be 18.00 (40.0 µg/ml), 6.43
(45.0 µg/ml), 17.00 (50.0 µg/ml) and 10.60 (55.0 µg/ml). No indication of potential clastogenic effects and/or chromosomal aberrations was found in all dose groups evaluated.
In experiment II without metabolic activation the quotients of large/small colonies of the negative controls were found to be 7.33 and 8.89. For the
solvent controls the quotients noticed were 4.44 and 6.70. The quotients of the highest dose groups were found to be 9.67 (8.00 µg/ml), 7.63 (10.0 µg/ml), 12.25 (12.0 µg/ml) and 5.25 (16.0 µg/ml). No indication of potential clastogenic effects and/or chromosomal aberrations was found in
all dose groups evaluated.
CONCLUSION
In conclusion, in the described mutagenicity test under the experimental conditions reported, the test item is considered to be
non-mutagenic in the mouse lymphoma thymidine kinase locus using the cell line L5178Y. - Remarks on result:
- other: all strains/cell types tested
- Remarks:
- Migrated from field 'Test system'.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information):
negative
In conclusion, in the described mutagenicity test under the experimental conditions reported, the test item oleic-acid based IQAC, DMS quaternised is considered to be non-mutagenic in the mouse lymphoma thymidine kinase locus using the cell line L5178Y. - Executive summary:
In a mammalian gene mutation assay, L5178 Y (mouse lympoma thymidine kinase locus) cells cultured in vitro were exposed to the oleic-acid based IQAC; DMS quaternised (98 % a.i.) at the following concentrations:
Experiment I
- with metabolic activation: 2.50, 5.00, 7.50, 10.0, 12.5, 15.0, 20.0, 40.0 and 60.0 µg/ml
- without metabolic activation: 1.00, 3.00, 5.00, 10.0, 12.0, 16.0, 18.0, 20.0, 25.0 and 30.0 µg/ml
Experiment II
- with metabolic activation: 10.0, 15.0, 20.0, 25.0, 30.0, 35.0, 40.0, 45.0, 50.0 and 55.0 µg/ml
- without metabolic activation: 0.50, 1.00, 2.00, 4.00, 6.00, 8.00, 10.0, 12.0 and 16.0 µg/ml
The oleic-acid based IQAC, DMS quaternised was tested up to cytotoxic concentrations (>/= 16.0 µg/ml without metaboic activation and >/= 40.0 µg/ ml with metabolic activation). The positive controls induced the appropriate responses in the corresponding strains. There was no evidence of increased number of induced mutant colonies over background.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.